EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.416
https://www.valueinhealthjournal.com/article/S1098-3015(22)00617-9/fulltext
Section Title :
Section Order :
10365
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00617-9&doi=10.1016/j.jval.2022.04.416